Lalitpur pharma park: U.P. eyes one lakh crore investment, 1.5 lakh jobs

A pharma park spanning over 2,000 acres is to come up in Lalitpur, which will accommodate up to 70 manufacturing units.

The park is expected to attract an investment of Rs 1 lakh crore into the state, a press statement issued by the state government on Monday read.

This development is expected to generate more than 1.5 lakh job opportunities. Supporting industries related to pharma will indirectly create 3 lakh jobs, the release read further.

The state government will provide 94 plots in the park, in which plots will range from five acres to 50 acres. This includes three plots of 50 acres, five of 30 acres, eight of 20 acres, 15 plots of 15 acres, 20 plots of 10 acres, and 43 plots of five acres each. Out of the total area, the government will provide plots for industry set-ups in 53%, while the remaining portion will be allocated for other facilities, the statement read.

The park will also allocate 60 acres for residential (housing group) and 40 acres for commercial activities.

Ensuring smooth power supply and upgrading the airport is also in the plan. Additionally, a check-dam reservoir and a pumping station will be constructed on the Jamni River at an estimated cost of 60 crore.

Along with this, about 12 types of concessions will be given to the industry to set up plants in UP. These include interest subsidy, SGST refund, exemption from stamp duty and registration charges, electric duty exemption, EPF reimbursement, hire subsidy, air cargo handling subsidy, patent registration subsidy, quality certification subsidy, skill development incentive, and others.

Related Posts

ONESOURCE’s partner receives USFDA tentative approval for Semaglutide Injection

OneSource Speciality Pharma announced that its partner Orbicular Pharmaceutical Technologies (Orbicular), together with its U.S.-based front-end partner (the ANDA holder), has secured tentative U.S. Food and Drug Administration (FDA) approval…

Ajanta Pharma gets USFDA Form 483 with five observations at Paithan plant

Ajanta Pharma said the United States Food and Drug Administration (USFDA) has completed an inspection at its Paithan manufacturing facility in Maharashtra, conducted between 13 April and 21 April 2026.…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

ONESOURCE’s partner receives USFDA tentative approval for Semaglutide Injection

ONESOURCE’s partner receives USFDA tentative approval for Semaglutide Injection

Ajanta Pharma gets USFDA Form 483 with five observations at Paithan plant

Ajanta Pharma gets USFDA Form 483 with five observations at Paithan plant

Obesity drug market to gain as Indians pop the pill and Chinese bring more

Obesity drug market to gain as Indians pop the pill and Chinese bring more

Aurobindo Pharma Rs 800 Cr Buyback Opens Apr 23

Aurobindo Pharma Rs 800 Cr Buyback Opens Apr 23

Boehringer Ingelheim launches AI centre for pharma research in London

Boehringer Ingelheim launches AI centre for pharma research in London

Pharma exports rose 2% to over $31 billion in FY26 despite sharp decline in March

Pharma exports rose 2% to over $31 billion in FY26 despite sharp decline in March